bcor突变的常规和去分化软骨肉瘤:临床病理研究

IF 2.8 2区 医学 Q2 GENETICS & HEREDITY
Diego M. Montoya-Cerrillo, Mark G. Evans, Andrew Elliott, Renzo Calderon Anyosa, Jaylou Velez Torres, Elizabeth A. Montgomery, Francis J. Hornicek, H. Thomas Temple, Brooke Crawford, Jonathan Trent, Emily E. Jonczak, Gina D'Amato, Andrew E. Rosenberg
{"title":"bcor突变的常规和去分化软骨肉瘤:临床病理研究","authors":"Diego M. Montoya-Cerrillo,&nbsp;Mark G. Evans,&nbsp;Andrew Elliott,&nbsp;Renzo Calderon Anyosa,&nbsp;Jaylou Velez Torres,&nbsp;Elizabeth A. Montgomery,&nbsp;Francis J. Hornicek,&nbsp;H. Thomas Temple,&nbsp;Brooke Crawford,&nbsp;Jonathan Trent,&nbsp;Emily E. Jonczak,&nbsp;Gina D'Amato,&nbsp;Andrew E. Rosenberg","doi":"10.1002/gcc.70068","DOIUrl":null,"url":null,"abstract":"<p>Conventional and dedifferentiated chondrosarcoma encompass a group of malignant neoplasms that produce cartilaginous matrix and arise within or on the surface of bone. Conventional chondrosarcomas are graded on a three-tiered scale, whereas dedifferentiated chondrosarcoma is typically not graded but is considered a high-grade sarcoma and represents the most aggressive subtype with a poor prognosis. <i>IDH1</i> (isocitrate dehydrogenase-1) and <i>I</i><i>DH2</i> (isocitrate dehydrogenase-2) are the most commonly mutated genes in conventional and dedifferentiated chondrosarcoma, followed in frequency by <i>COL2A1</i> and <i>TP53</i>. <i>IDH1/2</i> driver mutations are also commonly found in enchondroma, considered a benign precursor lesion of chondrosarcoma, and other malignancies such as gliomas, cholangiocarcinoma, and acute myeloid leukemia. In acute myeloid leukemia, the presence of concurrent <i>BCOR</i> (BCL-6 corepressor) loss-of-function mutations has been linked to disease relapse and resistance to treatment with IDH inhibitors. After identifying an index case of conventional chondrosarcoma with unusually aggressive clinical evolution, we investigated the clinicopathological features of 12 cases of <i>BCOR</i>-mutated conventional and dedifferentiated chondrosarcomas against a control group of 15 <i>BCOR</i>-wildtype (WT) cases to determine whether <i>BCOR</i>-mutated tumors had patterns of biological progression different from tumors with intact <i>BCOR</i>. All identified <i>BCOR</i> alterations led to loss-of-function by either missense or nonsense mutations. The prevalence of <i>BCOR</i> mutations occurred in 5% of conventional and dedifferentiated chondrosarcoma, and these were associated with larger tumor size (<i>p</i> = 0.024), metastasis at the time of diagnosis (<i>p</i> ≤ 0.001) and higher T category (3–4 vs. 1–2) (<i>p</i> = 0.009). Although larger studies are necessary to clarify the full impact of <i>BCOR</i> mutations on patients with conventional and dedifferentiated chondrosarcoma, our data indicate that <i>BCOR</i> genetic aberrations are associated with adverse clinical features.</p>","PeriodicalId":12700,"journal":{"name":"Genes, Chromosomes & Cancer","volume":"64 9","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/gcc.70068","citationCount":"0","resultStr":"{\"title\":\"BCOR-Mutated Conventional and Dedifferentiated Chondrosarcoma: A Clinicopathologic Study\",\"authors\":\"Diego M. Montoya-Cerrillo,&nbsp;Mark G. Evans,&nbsp;Andrew Elliott,&nbsp;Renzo Calderon Anyosa,&nbsp;Jaylou Velez Torres,&nbsp;Elizabeth A. Montgomery,&nbsp;Francis J. Hornicek,&nbsp;H. Thomas Temple,&nbsp;Brooke Crawford,&nbsp;Jonathan Trent,&nbsp;Emily E. Jonczak,&nbsp;Gina D'Amato,&nbsp;Andrew E. Rosenberg\",\"doi\":\"10.1002/gcc.70068\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Conventional and dedifferentiated chondrosarcoma encompass a group of malignant neoplasms that produce cartilaginous matrix and arise within or on the surface of bone. Conventional chondrosarcomas are graded on a three-tiered scale, whereas dedifferentiated chondrosarcoma is typically not graded but is considered a high-grade sarcoma and represents the most aggressive subtype with a poor prognosis. <i>IDH1</i> (isocitrate dehydrogenase-1) and <i>I</i><i>DH2</i> (isocitrate dehydrogenase-2) are the most commonly mutated genes in conventional and dedifferentiated chondrosarcoma, followed in frequency by <i>COL2A1</i> and <i>TP53</i>. <i>IDH1/2</i> driver mutations are also commonly found in enchondroma, considered a benign precursor lesion of chondrosarcoma, and other malignancies such as gliomas, cholangiocarcinoma, and acute myeloid leukemia. In acute myeloid leukemia, the presence of concurrent <i>BCOR</i> (BCL-6 corepressor) loss-of-function mutations has been linked to disease relapse and resistance to treatment with IDH inhibitors. After identifying an index case of conventional chondrosarcoma with unusually aggressive clinical evolution, we investigated the clinicopathological features of 12 cases of <i>BCOR</i>-mutated conventional and dedifferentiated chondrosarcomas against a control group of 15 <i>BCOR</i>-wildtype (WT) cases to determine whether <i>BCOR</i>-mutated tumors had patterns of biological progression different from tumors with intact <i>BCOR</i>. All identified <i>BCOR</i> alterations led to loss-of-function by either missense or nonsense mutations. The prevalence of <i>BCOR</i> mutations occurred in 5% of conventional and dedifferentiated chondrosarcoma, and these were associated with larger tumor size (<i>p</i> = 0.024), metastasis at the time of diagnosis (<i>p</i> ≤ 0.001) and higher T category (3–4 vs. 1–2) (<i>p</i> = 0.009). Although larger studies are necessary to clarify the full impact of <i>BCOR</i> mutations on patients with conventional and dedifferentiated chondrosarcoma, our data indicate that <i>BCOR</i> genetic aberrations are associated with adverse clinical features.</p>\",\"PeriodicalId\":12700,\"journal\":{\"name\":\"Genes, Chromosomes & Cancer\",\"volume\":\"64 9\",\"pages\":\"\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2025-09-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/gcc.70068\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Genes, Chromosomes & Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/gcc.70068\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"GENETICS & HEREDITY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Genes, Chromosomes & Cancer","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/gcc.70068","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
引用次数: 0

摘要

常规和去分化软骨肉瘤包括一组恶性肿瘤,产生软骨基质,出现在骨内或骨表面。传统的软骨肉瘤按三级分级,而去分化软骨肉瘤通常不分级,但被认为是高级别肉瘤,代表最具侵袭性的亚型,预后较差。IDH1(异柠檬酸脱氢酶-1)和IDH2(异柠檬酸脱氢酶-2)是常规和去分化软骨肉瘤中最常见的突变基因,其次是COL2A1和TP53。IDH1/2驱动突变也常见于软骨肉瘤、胶质瘤、胆管癌和急性髓系白血病等恶性肿瘤的良性前体病变内软骨瘤。在急性髓系白血病中,同时存在BCL-6协同抑制因子功能丧失突变与疾病复发和对IDH抑制剂治疗的耐药性有关。在确定了一例具有异常侵袭性临床进展的常规软骨肉瘤的指标病例后,我们研究了12例BCOR突变的常规和去分化软骨肉瘤的临床病理特征,并与对照组的15例BCOR野生型(WT)病例进行了对比,以确定BCOR突变的肿瘤是否具有不同于完整bor肿瘤的生物学进展模式。所有鉴定出的BCOR改变都通过错义突变或无义突变导致功能丧失。5%的常规和去分化软骨肉瘤发生BCOR突变,这些突变与较大的肿瘤大小(p = 0.024)、诊断时的转移(p≤0.001)和较高的T分类(3-4比1-2)相关(p = 0.009)。尽管需要更大规模的研究来阐明BCOR突变对常规和去分化软骨肉瘤患者的全面影响,但我们的数据表明,BCOR基因畸变与不良临床特征有关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

BCOR-Mutated Conventional and Dedifferentiated Chondrosarcoma: A Clinicopathologic Study

BCOR-Mutated Conventional and Dedifferentiated Chondrosarcoma: A Clinicopathologic Study

Conventional and dedifferentiated chondrosarcoma encompass a group of malignant neoplasms that produce cartilaginous matrix and arise within or on the surface of bone. Conventional chondrosarcomas are graded on a three-tiered scale, whereas dedifferentiated chondrosarcoma is typically not graded but is considered a high-grade sarcoma and represents the most aggressive subtype with a poor prognosis. IDH1 (isocitrate dehydrogenase-1) and IDH2 (isocitrate dehydrogenase-2) are the most commonly mutated genes in conventional and dedifferentiated chondrosarcoma, followed in frequency by COL2A1 and TP53. IDH1/2 driver mutations are also commonly found in enchondroma, considered a benign precursor lesion of chondrosarcoma, and other malignancies such as gliomas, cholangiocarcinoma, and acute myeloid leukemia. In acute myeloid leukemia, the presence of concurrent BCOR (BCL-6 corepressor) loss-of-function mutations has been linked to disease relapse and resistance to treatment with IDH inhibitors. After identifying an index case of conventional chondrosarcoma with unusually aggressive clinical evolution, we investigated the clinicopathological features of 12 cases of BCOR-mutated conventional and dedifferentiated chondrosarcomas against a control group of 15 BCOR-wildtype (WT) cases to determine whether BCOR-mutated tumors had patterns of biological progression different from tumors with intact BCOR. All identified BCOR alterations led to loss-of-function by either missense or nonsense mutations. The prevalence of BCOR mutations occurred in 5% of conventional and dedifferentiated chondrosarcoma, and these were associated with larger tumor size (p = 0.024), metastasis at the time of diagnosis (p ≤ 0.001) and higher T category (3–4 vs. 1–2) (p = 0.009). Although larger studies are necessary to clarify the full impact of BCOR mutations on patients with conventional and dedifferentiated chondrosarcoma, our data indicate that BCOR genetic aberrations are associated with adverse clinical features.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Genes, Chromosomes & Cancer
Genes, Chromosomes & Cancer 医学-遗传学
CiteScore
7.00
自引率
8.10%
发文量
94
审稿时长
4-8 weeks
期刊介绍: Genes, Chromosomes & Cancer will offer rapid publication of original full-length research articles, perspectives, reviews and letters to the editors on genetic analysis as related to the study of neoplasia. The main scope of the journal is to communicate new insights into the etiology and/or pathogenesis of neoplasia, as well as molecular and cellular findings of relevance for the management of cancer patients. While preference will be given to research utilizing analytical and functional approaches, descriptive studies and case reports will also be welcomed when they offer insights regarding basic biological mechanisms or the clinical management of neoplastic disorders.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信